Intensive glucose control offers lasting reduction in risk of ESKD

Intensive glucose control offers lasting reduction in risk of ESKD

(HealthDay)—For patients with type 2 diabetes, intensive glucose control has long-term benefits for preventing end-stage kidney disease (ESKD), according to a study published online March 22 in Diabetes Care.

Muh Geot Wong, M.D., Ph.D., from the University of Sydney, and colleagues examined the long-term effects of intensive on the risk of ESKD and other outcomes in survivors of the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Released Controlled Evaluation (ADVANCE) trial. A total of 8,494 ADVANCE participants, who had previously been randomized to intensive or standard glucose control, participated in a post-trial follow-up.

The researchers found that by the first post-trial visit, in-trial hemoglobin A1c differences disappeared. After 9.9 years of overall follow-up, the in-trial reduction in the risk of ESKD (seven versus 20 events; hazard ratio, 0.35; P = 0.02) persisted (29 versus 53 events; hazard ratio, 0.54; P < 0.01). Greater effects were seen in earlier-stage chronic kidney disease (P = 0.04) and at lower levels of baseline systolic (P = 0.01). The glucose lowering effects on death, cardiovascular death, or major cardiovascular event risks did not vary according to levels of (P > 0.26).

"Intensive glucose control was associated with a long-term reduction in ESKD, without evidence of any increased risk of cardiovascular events or death," the authors write. "These benefits were greater with preserved function and with well-controlled blood pressure."

Several authors disclosed financial ties to the pharmaceutical industry; the ADVANCE trial and ADVANCE-ON follow-up study were partially funded by grants from Servier.

More information: Abstract
Full Text (subscription or payment may be required)

Journal information: Diabetes Care

Copyright © 2016 HealthDay. All rights reserved.

Citation: Intensive glucose control offers lasting reduction in risk of ESKD (2016, March 29) retrieved 13 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Glycemic variability elevates risk of vascular events, death


Feedback to editors